LS9 Inc., a startup founded in 2005 to apply synthetic biology technology to production of proprietary biofuels (earlier post) has secured $5 million in Series A funding from Flagship Ventures and Khosla Ventures and has established its Scientific Advisory Board (SAB).
The funding and SAB appointments will accelerate LS9’s plans to pursue industrial applications of synthetic biology.
Two new members join company founders Chris Somerville and George Church, and two others on the SAB: Christopher Walsh and Anthony Sinskey.
Prof. Walsh is an expert in enzyme stereochemistry and reaction mechanisms and has been Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School since 1991. Prof. Sinskey is Professor of Microbiology and Health Sciences and Technology at MIT and is a leader in the area of metabolic engineering.
The newly appointed members will join existing SAB members Chaitan Khosla and Edward DeLong. Prof. Khosla is Professor of Chemical Engineering and Chemistry at Stanford University and is at the forefront of research on polyketide synthases as paradigms for modular catalysis. Prof. DeLong is developing the field of microbial community genomics and metagenomics and is the Moore Foundation Professor of Microbial Genomics at MIT.